232 related articles for article (PubMed ID: 3091770)
21. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms.
Sossi V; de la Fuente-Fernández R; Holden JE; Schulzer M; Ruth TJ; Stoessl J
J Cereb Blood Flow Metab; 2004 Aug; 24(8):869-76. PubMed ID: 15362717
[TBL] [Abstract][Full Text] [Related]
22. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
[TBL] [Abstract][Full Text] [Related]
24. Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis.
Gjedde A; Léger GC; Cumming P; Yasuhara Y; Evans AC; Guttman M; Kuwabara H
J Neurochem; 1993 Oct; 61(4):1538-41. PubMed ID: 8377003
[TBL] [Abstract][Full Text] [Related]
25. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
[TBL] [Abstract][Full Text] [Related]
26. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
Thobois S; Ribeiro MJ; Lohmann E; Dürr A; Pollak P; Rascol O; Guillouet S; Chapoy E; Costes N; Agid Y; Remy P; Brice A; Broussolle E;
Arch Neurol; 2003 May; 60(5):713-8. PubMed ID: 12756135
[TBL] [Abstract][Full Text] [Related]
27. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.
Sossi V; de La Fuente-Fernández R; Holden JE; Doudet DJ; McKenzie J; Stoessl AJ; Ruth TJ
J Cereb Blood Flow Metab; 2002 Feb; 22(2):232-9. PubMed ID: 11823721
[TBL] [Abstract][Full Text] [Related]
28. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
Nagasawa H; Tanji H; Itoh M; Itoyama Y
Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
[TBL] [Abstract][Full Text] [Related]
29. A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.
Gallagher CL; Johnson SC; Bendlin BB; Chung MK; Holden JE; Oakes TR; Brooks BR; Konopacki RA; Dogan S; Abbs JH; Xu G; Nickles RJ; Pyzalski RW; Dejesus OT; Brown WD
Brain Imaging Behav; 2011 Sep; 5(3):203-11. PubMed ID: 21556744
[TBL] [Abstract][Full Text] [Related]
30. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
Lyoo CH; Ryu YH; Lee MJ; Lee MS
Acta Neurol Scand; 2012 Nov; 126(5):344-9. PubMed ID: 22380639
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography (PET) in "pure akinesia".
Taniwaki T; Hosokawa S; Goto I; Fujii N; Otsuka M; Kuwabara Y; Ichiya Y; Hasuo K; Kato M
J Neurol Sci; 1992 Jan; 107(1):34-9. PubMed ID: 1578232
[TBL] [Abstract][Full Text] [Related]
32. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
Innis RB; Seibyl JP; Scanley BE; Laruelle M; Abi-Dargham A; Wallace E; Baldwin RM; Zea-Ponce Y; Zoghbi S; Wang S
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11965-9. PubMed ID: 8265656
[TBL] [Abstract][Full Text] [Related]
33. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease.
Menza MA; Mark MH; Burn DJ; Brooks DJ
J Neuropsychiatry Clin Neurosci; 1995; 7(2):176-9. PubMed ID: 7626960
[TBL] [Abstract][Full Text] [Related]
34. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
[TBL] [Abstract][Full Text] [Related]
35. Striatal dopamine distribution in parkinsonian patients during life.
Nahmias C; Garnett ES; Firnau G; Lang A
J Neurol Sci; 1985 Jul; 69(3):223-30. PubMed ID: 3928823
[TBL] [Abstract][Full Text] [Related]
36. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd KG; Davidson L; Hornykiewicz O
J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
[TBL] [Abstract][Full Text] [Related]
37. Study on the striatal dopamine availability in Parkinson's disease.
Indo T
Jpn J Med; 1984 Aug; 23(3):228-36. PubMed ID: 6492486
[TBL] [Abstract][Full Text] [Related]
38. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.
Hilker R; Klein C; Hedrich K; Ozelius LJ; Vieregge P; Herholz K; Pramstaller PP; Heiss WD
Neurosci Lett; 2002 Apr; 323(1):50-4. PubMed ID: 11911988
[TBL] [Abstract][Full Text] [Related]
39. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects.
Laakso A; Vilkman H; Bergman J; Haaparanta M; Solin O; Syvälahti E; Salokangas RK; Hietala J
Biol Psychiatry; 2002 Oct; 52(7):759-63. PubMed ID: 12372667
[TBL] [Abstract][Full Text] [Related]
40. Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease.
Tedroff J; Aquilonius SM; Hartvig P; Lundqvist H; Gee AG; Uhlin J; Långström B
Acta Neurol Scand; 1988 Mar; 77(3):192-201. PubMed ID: 3259784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
